DelveInsight Blog
Map the latest in Pharmaceutical, Healthcare, Medical Devices and Biotech Space with DelveInsight’s panoramic market analysis while the Pharma Industry continues to rapidly evolve with several approvals,failures, acquisitions, and partnerships teeing up the domain.
Top 8 Breakthrough Gene Therapies for Retinitis Pigmentosa Treatment
Gene therapy is becoming a promising solution for retinal degenerative diseases, as the retina offers an excellent setting for studying and treating eye conditions. Importantly, it was the first tissue to receive approved gene therapy for genetic disorders in the United States. To date, only one retinitis pigmentosa treatment regimen, LUXTURNA (developed by Spark Therapeutics), has been approved in the United States. LUXTURNA, the only FDA-approved gene therapy for retinitis pigmentosa treatment, also known as voretigene neparvovec-rzyl, is a one-time gene therapy designed for patients with biallelic RPE65 mutation-associated retinal…
STRATA Skin Sciences’ XTRAC Momentum™ 1.0 Device Approved in Japan; eCential Robotics Received FDA 510(k) Clearance for Spine Navigation and Robotic-Assistance Device; MicroVention Announced the Results of the Clinical Evaluation of WEB™ 17 Device; Neuspera Medical, Inc.’s SANS-UUI Pivotal Clinical Trial; GE HealthCare Announced an Agreement to Acquire the Clinical Artificial Intelligence Business; Sutter Health Implemented World’s First Wearable Doppler Ultrasound Patch
STRATA Skin Sciences Announced That the Ministry of Health, Labor and Welfare Approved the XTRAC Momentum™ 1.0 Device in Japan, Specifically Designed to Treat Inflammatory Skin Conditions On July 22, 2024, STRATA Skin Sciences, Inc., a medical technology company specializing in developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announced the approval of its XTRAC Momentum™ 1.0 device by the Ministry of Health, Labor and Welfare of Japan. “With this regulatory approval, we are now able to offer the Momentum™ device -- our most advanced excimer…
Mobile Health Apps for Obesity Treatment: A Modern Solution to a Growing Problem
Obesity is the second leading cause of preventable death, associated with a range of inflammatory conditions that contribute to cardiovascular disease, diabetes, respiratory problems, mental health issues, hypertension, obstructive sleep apnea, cancer, and high cholesterol. This represents a significant public health challenge that has been intensifying over the past fifty years. Obesity rates have been rising among both children and adults in both developed and developing countries. According to DelveInsight, ~196 million people across the seven major markets were living with obesity as of 2023, with these numbers expected to…
-Agonist.png "Toll-like Receptors Agonist")
